Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1755-1763

  Leu, Jyh Der ^a,d   Wang, Chung Yih ^b   Tsai, Han Yi ^c   Lin, I Feng ^c   Chen, Ran Chou ^a,c   Lee, Yi Jang ^a,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

Asian Taiwanese; Breast cancer risk; MDM2 SNP309; p53 codon R72P

Indexed keywords

ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER RISK; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954536556     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1254     Document Type: Article

References (51)

1. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98: 1382-1396, 2006.
2. Eccles D and Tapper W: The influence of common polymorphisms on breast cancer. Cancer Treat Res 155: 15-32, 2010.
3. Speirs V and Shaaban AM: The rising incidence of male breast cancer. Breast Cancer Res Treat 115: 429-430, 2009.
4. Jin S and Levine AJ: The p53 functional circuit. J Cell Sci 114: 4139-4140, 2001. (Pubitemid 33138651)
5. Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993. (Pubitemid 24000599)
6. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855, 1992.
7. Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110, 2006. (Pubitemid 43844932)
8. Bond GL, Hu W and Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481-5484, 2005. (Pubitemid 40911143)
9. Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004. (Pubitemid 39535748)
10. Bond GL and Levine AJ: A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26: 1317-1323, 2007. (Pubitemid 46328460)
11. Schmidt MK, Reincke S, Broeks A, et al: Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67: 9584-9590, 2007. (Pubitemid 47535950)
12. Sun YF, Leu JD, Chen SM, Lin IF and Lee YJ: Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9: 13, 2009.
13. Wasielewski M, Nagel JH, Brekelmans C, et al: MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 104: 153-157, 2007. (Pubitemid 47084228)
14. Lum SS, Chua HW, Li H, et al: MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29: 754-761, 2008. (Pubitemid 351494162)
15. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E and Papa MZ: MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111: 497-504, 2008.
16. Economopoulos KP and Sergentanis TN: Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 120: 211-216, 2010.
17. Pietsch EC, Humbey O and Murphy ME: Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611, 2006.
18. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003. (Pubitemid 36278852)
19. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004. (Pubitemid 37541770)
20. Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500, 2006. (Pubitemid 43901670)
21. Siddique MM, Balram C, Fiszer-Maliszewska L, et al: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14: 2245-2252, 2005. (Pubitemid 41603274)
22. Zhang Z, Wang M, Wu D, et al: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 120: 509-517, 2010.
23. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
24. Freedman DA and Levine AJ: Regulation of the p53 protein by the MDM2 oncoprotein - Thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 59: 1-7, 1999. (Pubitemid 29062945)
25. Dharel N, Kato N, Muroyama R, et al: MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12: 4867-4871, 2006. (Pubitemid 44338572)
26. Grochola LF, Muller TH, Bond GL, Taubert H, Udelnow A and Wurl P: MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation. Pancreas 39: 76-80, 2010.
27. Idbaih A, Boisselier B, Marie Y, et al: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res 1198: 16-20, 2008.
28. Bougeard G, Baert-Desurmont S, Tournier I, et al: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533, 2006. (Pubitemid 43927330)
29. Ashton KA, Proietto A, Otton G, et al: Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 113: 109-114, 2009.
30. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J and Scott RJ: MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120: 563-565, 2007. (Pubitemid 44969027)
31. Toffoli G, Biason P, Russo A, et al: Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15: 3550-3556, 2009.
32. Horikawa Y, Nadaoka J, Saito M, et al: Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20: 49-55, 2008.
33. Schmidt MK, Tommiska J, Broeks A, et al: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11: R89, 2009.
34. Lang A, Palmeback Wegman P and Wingren S: The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep 22: 575-579, 2009.
35. Singh V, Rastogi N, Mathur N, Singh K and Singh MP: Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18: 48-57, 2008. (Pubitemid 350184342)
36. Cox DG, Deer D, Guo Q, et al: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 18: 621-625, 2007. (Pubitemid 46883679)
37. Walsh CS, Miller CW, Karlan BY and Koeffler HP: Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104: 660-664, 2007.
38. Xu Y, Yao L, Zhao A, et al: Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122: 2761-2766, 2008. (Pubitemid 351631378)
39. Pine SR, Mechanic LE, Bowman ED, et al: MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15: 1559-1561, 2006. (Pubitemid 44299333)
40. Millikan RC, Heard K, Winkel S, et al: No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15: 175-177, 2006.
41. Krekac D, Brozkova K, Knoflickova D, et al: MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74: 84-87, 2008. (Pubitemid 351915014)
42. Hu Z, Jin G, Wang L, Chen F, Wang X and Shen H: MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16: 2717-2723, 2007. (Pubitemid 351196328)
43. Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW and Eccles DM: Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6: 80, 2006.
44. Campbell IG, Eccles DM and Choong DY: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240: 195-197, 2006. (Pubitemid 44093819)
45. Ma H, Hu Z, Zhai X, et al: Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240: 261-267, 2006. (Pubitemid 44093826)
46. Boersma BJ, Howe TM, Goodman JE, et al: Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98: 911-919, 2006. (Pubitemid 44018921)
47. Menin C, Scaini MC, De Salvo GL, et al: Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98: 285-288, 2006. (Pubitemid 43264712)
48. Leu JD, Lin IF, Sun YF, Chen SM, Liu CC and Lee YJ: Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 15: 5592-5597, 2009.
49. Ottini L, Palli D, Rizzo S, Federico M, Bazan V and Russo A: Male breast cancer. Crit Rev Oncol Hematol 73: 141-155, 2010.
50. Anderson WF, Jatoi I, Tse J and Rosenberg PS: Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28: 232-239, 2010.
51. Post SM, Quintas-Cardama A, Pant V, et al: A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18: 220-230, 2010.